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Abstract
Background: All spinocerebellar ataxias (SCAs) are rare diseases. SCA1, 2, 3 and 6 are the four most common SCAs,
all caused by expanded polyglutamine-coding CAG repeats. Their pathomechanisms are becoming increasingly
clear and well-designed clinical trials will be needed.
Methods: To characterize the clinical manifestations of spinocerebellar ataxia (SCA) 1, 2, 3 and 6 and their natural
histories in the United States (US), we conducted a prospective multicenter study utilized a protocol identical to the
European consortium study, using the Scale for the Assessment and Rating of Ataxia (SARA) score as the primary
outcome, with follow-ups every 6 months up to 2 years.
Results: We enrolled 345 patients (60 SCA1, 75 SCA2, 138 SCA3 and 72 SCA6) at 12 US centers. SCA6 patients had
a significantly later onset, and SCA2 patients showed greater upper-body ataxia than patients with the remaining
SCAs. The annual increase of SARA score was greater in SCA1 patients (mean ± SE: 1.61 ± 0.41) than in SCA2
(0.71 ± 0.31), SCA3 (0.65 ± 0.24) and SCA6 (0.87 ± 0.28) patients (p = 0.049). The functional stage also worsened faster
in SCA1 than in SCA2, 3 and 6 (p = 0.002).
Conclusions: The proportions of different SCA patients in US differ from those in the European consortium study,
but as in the European patients, SCA1 progress faster than those with SCA2, 3 and 6. Later onset in SCA6 and
greater upper body ataxia in SCA2 were noted. We conclude that progression rates of these SCAs were comparable
between US and Europe cohorts, suggesting the feasibility of international collaborative clinical studies.
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Background
Spinocerebellar ataxias (SCAs) are a group of autosomal
dominant disorders of motor coordination caused by de-
generation of the cerebellum and its afferent or efferent
pathways. Among them, SCA1, 2, 3, 6, 7 and 17, and
dentatorubral pallidoluysian atrophy are caused by an
expansion of a polyglutamine (polyQ)-coding CAG re-
peat within the respective genes [1-3]. Although these
SCAs are all rare, with an estimated prevalence of less
than 4/100,000 for each SCA [4-8], SCA1, 2, 3 and 6 are
the most common among all SCAs. Currently available
data suggest that these SCAs are caused by a toxic gain
of function by the expanded polyQ in the context of dif-
ferent proteins coded by the respective genes. Although
SCA1, 2, 3 and 6 are known to cause progressively se-
vere disability and often premature death, there are no
effective treatments. However, the increasing under-
standing of the pathogenic mechanisms and develop-
ment of new drug development technologies have raised
hopes for novel treatments. The knowledge of natural
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history and availability of cohorts of clinically character-
ized research subjects are essential for well-designed
clinical trials of these SCAs.
Cross-sectional studies have provided characterization
of clinical phenotypes of SCA1, 2, 3 and 6 [1-3]. European
investigators have studied the natural history of SCA1,
2, 3 and 6 by obtaining scores of the Scale for the
Assessment and Rating of Ataxia (SARA) [9,11] and
SCA Functional Index (SCAFI) [12,13]. For a parallel ef-
fort in the US, we have established the Clinical Research
Consortium for Spinocerebellar Ataxias (CRC-SCA) as
one of the 19 Rare Disease Consortia (RDC) of the NIH
Rare Disease Clinical Research Network (RDCRN) [14]
to investigate the natural history of SCA1, 2, 3 and 6
in 2009. The use of the same measures as those used
in the European studies allows us to directly compare
the data in two different patient populations across
the Atlantic.
Methods
Patients
In this prospective study, subjects were recruited from
ataxia clinics at 12 participating centers of the CRC-SCA
at Columbia University, Emory University, Massachusetts
General Hospital, Johns Hopkins University, University
of California Los Angeles, University of California San
Francisco, University of Chicago, University of Florida,
University of Michigan, University of Minnesota, University
of South Florida and University of Utah. At each center,
study subjects were consecutively recruited from patients
visiting the clinic specialized in ataxia or movement disor-
ders. The patients seen in the clinic were referred by pa-
tients themselves, community physicians, local support
groups and the National Ataxia Foundation. We also uti-
lized the RDCRN Contact Registry to recruit study sub-
jects in the catchment region. Under a uniform protocol
approved by local IRBs, written informed consent was
obtained from each patient. The inclusion criteria were
1) DNA diagnosis of SCA1, 2, 3 or 6 in the study subject
or his/her affected family member(s), 2) phenotype con-
sistent with the DNA diagnosis, 3) willingness to partici-
pate in the study, AND 4) the age of 6 years and older.
The exclusion criteria were 1) known recessive, X-linked
or mitochondrial ataxias, 2) concomitant disorder(s) that
affect SARA and other ataxia measures used in this study,
OR 3) exclusion of SCA1, 2, 3 and 6 by DNA testing.
Genetic evaluation
After the enrollment, demographic data were obtained,
and all patients were asked to provide DNA samples for
SCA genotyping. DNA was extracted from blood leuko-
cytes from patients; however, the participation in the
genotyping study was not requirement for participating in
the natural history study. The genotyping was performed
in Dr. Stefan Pulst’s laboratory at University of Utah using
multiplex PCR followed by capillary electrophoresis with
internal standards to confirm the reports of commercial
DNA testing. For quality control two CEPH DNA samples
(1332-02 and 1347-02) were included in every run, and
re-genotyping and Sanger sequencing were performed in
10% of samples.
Clinical evaluation
The study started in April 2010 after all participating
sites received IRB approval. At the baseline visit, neuro-
logical examination, SARA, functional stage (physician’s
assessment of the patient’s overall function), timed 25-ft
walk test (T25FW), 9-hole pegboard test (9HPT), the
Unified Huntington’s disease Rating Scale functional as-
sessment (UHDRS IV), EQ-5D (quality of life) visual
analogue scale (EQVAS), Patient Global Impression, and
Physician Global Impression were completed. We also
estimated an abbreviated SCA Functional Index (SCAFI-
AB) score, a version of the SCAFI [12] which includes
the T25FW and 9HPT but not the PATA rate [12]. We
did not include the PATA rate because of the large data
variability in our pilot study (data not shown). The age
at the baseline visit and the age at onset, which was de-
fined as the age when the patient first noted gait ataxia
during walking in ordinary circumstances, were re-
corded. Results were electronically entered in the case
report form prepared by the CRC-SCA and the RDCRN
Data Monitoring Coordinating Center (DMCC) and
stored in the CRC-SCA Natural History Database at
DMCC. The clinical evaluation was performed at the
baseline visit and every six months thereafter until two
years from the baseline visit or until the end of August
2012 when the study was closed.
Statistical analyses
Statistical analyses were done at the DMCC. The cap-
acities for disease duration, patient age, and genotype
(mutant and normal repeat lengths) to predict SARA
scores in patients with SCA were determined by linear re-
gression analysis. Comparisons between SCAs were done
by ANOVA and Student t-test for parametric datasets.
SARA scores were correlated with the SCAFI-AB, 9HPT,
T25FW, UHDRS IV, SF36 and EQVAS data using Pearson
correlations and linear regression analyses. Correlations of
the SARA score with the Patient Global Impression and
the Physician Global Impression were assessed using
Spearman’s rank correlation coefficient. Significance of
SARA scores by the Patient Global Impression and the
Physician Global Impression was assessed using the
Kruskal-Wallis test. The frequency of observations in dif-
ferent SCAs was analyzed by chi-square test and Fisher’s
exact test, depending on sample size. Mixed modeling,
adjusting for repeated measurements, was used to estimate
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linear trends in SARA, T25FW, functional stage and 9HPT
scores overtime. All tests were two-sided and p < 0.05
was considered significant after adjusting for multiple
comparisons.
Results
Genotypes
Genotyping was confirmed in DNA samples from 287 of
the 345 subjects, including 50 SCA1, 60 SCA2, 111
SCA3 and 66 SCA6 patients. First, quality control was
ascertained. There was 100% concordance of the first
and second multiplex genotype which was performed in
10% randomly chosen samples. Sequence analysis showed
98.8% concordance with repeat number determined by
fragment sizing; the discordance by 1-3 repeats was found
in seven samples with long SCA3 alleles. Four additional
samples (1.4%) showed no or erroneous SCA1, 2, 3 or 6
expansion. The allele size differed from the commercial
testing result in 38% of samples by 1 repeat, 10% by 2
repeats and 6% by ≥3 repeats, suggesting the necessity
of independent repeat size determination for precise
genotyping in these SCAs.
Cross section data
A total of 345 patients, including 60 SCA1 (17.4%), 75
SCA2 (21.7%), 138 SCA3 (40.0%) and 72 SCA6 (20.9%)
were enrolled in the study from April 2010 to August
2012. The proportion of SCA3 (40.0%) patients in the
CRC-SCA cohort is larger and the proportion of SCA2
(21.7%) is smaller than those in the European study
population (SCA1: 117, 22.2%; SCA2: 163, 31.0%; SCA3:
139, 26.4%; SCA6: 107, 20.3%; p < 0.001 chi-square) [11].
The distributions of age, sex, age at onset, age at base-
line, duration of the disease and SARA Total Score at
the baseline of patients with each SCA are listed in
Table 1. SCA6 patients had significantly later onset of
the disease than those with SCA1, 2 or 3 (p < 0.001).
The male:female ratio of patients in each SCA was less
than 1.00, but did not significantly differ from 1.00 that
is expected from the autosomal dominant inheritance.
In 287 patients CAG repeat alleles were determined
and the genetic diagnosis was confirmed at the University
of Utah. The size of the expanded allele showed a signifi-
cant inverse correlation with the age at onset in pa-
tients with SCA1 (r = −0.608 p < 0.001), SCA2 (r = −0.449
p= 0.008), SCA3 (r =−0.690 p < 0.001), and SCA6 (r =−0.394
p < 0.001). However, the rate of increase of the SARA
Total Score, which was estimated from the baseline SARA
score and the duration of the disease, showed no correl-
ation with the CAG repeat size in any of the SCAs.
The mean onset of gait problems was earlier than the
onset of speech problems by 4.26 years in SCA1,
3.95 years in SCA2, 5.44 years in SCA3 and 5.08 years in
SCA6, and the onset of hand coordination problems by
3.77 years in SCA1, 4.07 years in SCA2, 5.66 years in
SCA3 and 3.07 years in SCA6. Overall, the onset of gait
problems was significantly earlier than the onset of speech
(p < 0.001) or hand coordination (p < 0.001) problems,
while the onset of speech showed no significant differ-
ences from the onset of hand coordination problems.
The annual increase of the SARA Total Score was esti-
mated from the SARA Total Score and the duration of
disease at baseline in each SCA, assuming that SARA
Total Score was 0 at the disease onset (Table 1). The es-
timated annual increase of SARA Total Score was the
greatest (1.24 ± 0.07, mean ± SE) in SCA1 and signifi-
cantly (about 20%) greater than SCA2 (1.04 ± 0.04),
SCA3 (1.14 ± 0.04) and SCA6 (0.86 ± 0.05) (Figure 1)
(p = 0.003). The estimated increase of the SARA Total
Score showed no significant correlation with the number
of the corresponding expanded CAG repeats in SCA1
(r = 0.049, p = 0.740), SCA2 (r = 0.257, p = 0.053), SCA3
(r = 0.009, p = 0.928) or SCA6 (r = −0.123, p = 0.326).
Patients with SCA2 had greater difficulties with sitting
than patients with SCA1 (p = 0.015) and SCA6 (p = 0.002)
and with speech than SCA1 (p = 0.042), SCA3 (p = 0.001)
and SCA6 (p = 0.024) patients (Table 2). A total of 287
patients completed two trials of 9HPT by both hands;
the remaining 58 patients could not complete the en-
tire 9HPT routine due to physical inability, excessive
fatigue or unwillingness to complete the test. Patients
with SCA2 (n = 60) showed greater difficulties with 9HPT
than SCA1 (n = 45, p = 0.002), SCA3 (n = 118; p < 0.001)
and SCA6 (n = 65; p = 0.013) patients (Table 2). T25FW
Table 1 Baseline clinical characteristics and the increase in SARA Total Score estimated from the baseline score
and the duration of the disease
Age at
onset (yrs)
Age at
baseline (yrs)
Duration of
disease (yrs)
SARA
Total Score
Annual estimated
increase in SARA
Total Score
Standard error
of parameter
estimate
R2 R
Type of SCA N M/F Mean STD Mean STD Mean STD Mean STD
SCA1 60 0.79 40.41 11.40 49.28 12.64 8.93 6.89 14.16 8.39 1.2385 0.0728 0.7176 0.8471
SCA2 75 0.72 36.85 11.69 49.81 13.29 13.46 8.24 16.82 7.46 1.0367 0.0445 0.7882 0.8878
SCA3 138 0.93 39.25 11.81 50.34 12.04 10.92 7.32 14.98 8.78 1.1394 0.0402 0.7490 0.8654
SCA6 72 0.85 52.18 10.34 63.94 10.71 11.76 10.35 14.13 7.64 0.8575 0.0472 0.6980 0.8354
All 345 0.84 41.66 12.66 52.92 13.40 11.30 8.28 15.07 8.23 1.0471 0.0241 0.7344 0.8570
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was performed twice in 266 patients; of the remaining 79
patients, 73 could be tested neither for the first nor second
trial, and six patients were unable to be tested for the
second trial due to physical inability, excessive fatigue or
unwillingness to walk. The T25FW score (average of two
trials) did not significantly differ across SCA1, 2, 3 and 6
(p = 0.271). The above comparisons of difficulties of upper
and lower body functions among different SCAs suggest
that SCA2 patients have more upper body ataxia than gait,
stance and T25FW.
Longitudinal changes in the SARA scores
The longitudinal data of the SARA Total Score were
analyzed to determine the disease progression rate per
year of each SCA type using linear regression. Of the
345 patients, 14 (2 SCA1, 4 SCA2, 3 SCA3 and 5 SCA6
subjects) were followed for 24 months, 71 (5 SCA1, 17
SCA2, 30 SCA3 and 19 SCA6 subjects) for 18 months,
73 (16 SCA1, 12 SCA2, 27 SCA3 and 18 SCA6 subjects)
for 12 months and 80 (16 SCA1, 19 SCA2, 33 SCA3 and
12 SCA6 subjects) for 6 months. The remaining 107 had
only the baseline visit. One or two visits were missed by
14 patients during the follow-up period, including one
subject who was followed for 24 months, 7 patients
followed for 18 months and 6 patients followed for
12 months. To assess the disease progression rate, the
slope of the linear regression of SARA Total Score versus
the duration of time on-study (when measurements were
obtained) was estimated using mixed modeling adjusting
for repeated measurements. On average, the SARA Total
Score increased 1.00 ± 0.15 (mean ± SE, p < 0.001) points
per year for all SCA patients. The annual rate of change in
SARA Total Score was 1.61 ± 0.41 (p < 0.001) points per
year in patients with SCA1, 0.71 ± 0.31 (p = 0.024) points
per year with SCA2, 0.65 ± 0.24 (p = 0.006) points per year
with SCA3, and 0.87 ± 0.28 (p = 0.002) points per year
Figure 1 The SARA Total Score at the baseline and the duration of the disease. The SARA Total Score (Y axis) plotted against the duration
of disease (years; X axis) was calculated from the age at the baseline visit and the age at onset for each subject. Blue dots: SCA1 subjects, red dots:
SCA2 subjects, green dots: SCA3 subjects, and black dots: SCA6 subjects. The slope of the color-coded linear regression line indicates the estimated
average increase rate of the SARA Total Score of the SCA group.
Table 2 SARA subscores at baseline
SARA T25FW
(seconds)
9HPT
dominant
hand (seconds)
9HPT
non-dominant
hand (seconds)
Total
Score
Gait Stance Sitting Speech Finger
chase
Nose
finger
Alt hand
move
Heel
shin
Type of SCA N Mean Mean Mean Mean Mean Mean Mean Mean Mean N Mean N Mean N Mean
SCA1 60 14.16 3.49 2.40 0.60 1.89 1.29 1.19 1.52 1.78 50 13.01 49 44.46 44 43.33
SCA2 75 16.82 3.95 2.79 0.99 2.31 1.48 1.51 1.86 1.94 55 13.97 60 54.40 60 59.54
SCA3 138 14.98 4.15 2.80 0.77 1.74 1.22 1.07 1.54 1.69 99 12.36 120 41.06 118 42.98
SCA6 72 14.13 3.94 2.39 0.40 1.88 1.31 1.04 1.39 1.79 62 15.22 69 42.63 65 45.76
All 345 15.07 3.95 2.64 0.71 1.92 1.31 1.18 1.58 1.78 266 13.48 298 44.67 287 47.13
Ashizawa et al. Orphanet Journal of Rare Diseases 2013, 8:177 Page 4 of 8
http://www.ojrd.com/content/8/1/177
with SCA6 (Figure 2). The observed annual change in
SARA Total Score in patients with SCA1 was signifi-
cantly greater than the annual change in patients with
SCA2, 3 and 6 (p = 0.049). Changes in SARA Total
Score, Functional Stage, EQ-5D (EQVAS; Health State
Indicator) scores, and abbreviated SCAFI (SCAFI-AB)
were correlated with the Patient Global Impression
and the Physician Global Impression 6 months after the
baseline visit in Table 3. These changes were significantly
worse in the “Worse” group than in the “Stable/Same”
group and the “Improved/Better” group of the Patient
Global Impression (p = 0.019 for SARA Total Score,
p = 0.011 for Functional Stage, and p = 0.045 for SCAFI-AB)
except for EQ-5D (p = 0.561). For changes of the Physician
Global Impression only Sara Total Score (p < 0.001) and
Functional Stage (p = 0.040) were significantly different
between these groups.
In the 287 patients in whom the CAG repeat was ana-
lyzed, the expansion size showed no correlation with the
annual increase of the SARA Total Score estimated from
the baseline data in any of the SCAs we studied. How-
ever, the observed annual increase of the SARA Total
Score showed significant correlation with the age at
baseline in SCA2 (r = −0.48, p = 0.006), SCA3 (r = −0.26,
p = 0.042) and SCA6 (r = 0.30, p = 0.049) but not in
SCA1 (r = −0.16, p = 0.50). The speech SARA score de-
creased slightly (−0.036 points per year) in patients with
SCA2 whereas it worsened in patients with SCA1 (0.409
points per year), SCA3 (0.181 points per year) and SCA6
(0.196 points per year) (p < 0.001).
Longitudinal changes in functional stage
The functional stage worsened in patients with all SCAs
studied. The rate of worsening significantly differed
between patients with different SCA types. Patients with
SCA1 showed the fastest worsening of the functional
stage with an average increase of 0.411 ± 0.07 points
per year, and this was significantly greater than the
increase of 0.149 ± 0.05 points in patients with SCA2,
0.181 ± 0.04 points with SCA3 and 0.188 ± 0.05 points
with SCA6 (p = 0.002). There were no differences in
the worsening rate among SCA2, SCA3 and SCA6.
Longitudinal changes in timed measures
The average rate of change in the T25FW score in pa-
tients with SCA6 was 6.46 ± 2.09 seconds per year, which
was greater than −0.41 ± 2.81 per second per year with
SCA1 (p = 0.051), −2.09 ± 2.18 seconds per year with SCA2
(p = 0.005) and 0.02 ± 1.83 second per year with SCA3
(p = 0.021). The average rate of change in the 9HPT
score did not differ by SCA types; 3.6 seconds per
year in patients with SCA1 per year, 4.4 seconds per
year with SCA2, 7.1 seconds per year with SCA3 and
4.5 seconds per year with SCA6 (p = 0.390). Neither
did the mean change of the SCAFI-AB differ by SCA
types; -0.082 for patients with SCA1, -0.077 per year with
SCA2, -0.143 per year with SCA3 and −0.108 per year
with SCA6 (p = 0.238). The rate of the SCAFI-AB change
did not significantly correlate with the CAG repeat
expansion size.
Discussion
We have prospectively studied phenotypic characteristics
in 345 patients with SCA1, 2, 3 and 6 in the US and esti-
mated the rate of progression of ataxia. The patients en-
rolled in this study represent the largest group of SCA
patients studied in the US. Compared with data in the
earlier European study [11], our cohort showed a signifi-
cantly greater proportion of SCA3 and a smaller propor-
tion of SCA2. This difference of the SCA populations
between US and Europe may be attributable to immigra-
tion patterns in US. There was variability of SCA types
between sites, which may be due to settling patterns of
immigrants and tertiary referral patterns. The age at on-
set is variable in all SCAs, but SCA6 mostly began be-
tween ages of 50 to 60 years, whereas SCA1, 2 and 3
have an onset predominantly between 30 and 40 years,
confirming the previous European data [11].
The annual increase of the SARA Total Score in each
SCA was in good agreement between the rate estimated
from the cross-section data and the rate observed in the
longitudinal study in our US population (Figure 2).
SCA1 patients showed a faster increase of the SARA
Total Score than patients with SCA2, 3 and 6 in our
study. The worsening of the Functional Stage was also
significantly faster in SCA1 than three other SCAs, sug-
gesting that SCA1 progresses fastest among the four
most common SCAs. The published European data [11]
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Figure 2 Progression rate of SCA1, 2, 3 and 6. The annual rate of
increase of the SARA Total Score is shown. Black bar: Annual rate of
increase of the SARA Total Score was estimated from cross-section
SARA scores and the durations of the disease at the baseline visit.
Grey bar: The observed rate of increase of the SARA Total Score
during the longitudinal study. (*: p = 0.003, **: p = 0.049, compared
with SCA2, SCA3 and SCA6).
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also suggested that patients with SCA1 had faster pro-
gression than patients with SCA2, 3 and 6. The rate of
increase in our patients with SCA6 appears greater than
that in the European population. It should be noted that
our patients were evaluated every 6 months in contrast
to the annual evaluation in the European study. How-
ever, because many patients in our longitudinal study
did not completed the follow-up visits at the time the
NIH funding ended.
We included patients whose follow-up period was
shorter than 2 years in most subjects whereas all patients
in the European study completed the 2-year follow-ups.
Variability of the progression rate was smaller in the retro-
spective estimation than in the prospective analysis in
our series. This may point to some minimal duration of
follow-up that is needed to come to stable calculations of
the progression rate in the prospective study.
Although the mean progression rate appears to be fas-
ter in the European patients with SCA1, 2 or 3, it did
not significantly differ from the progression rate of our
cohort. Increasing the number of study subjects and the
duration of follow ups in our series could determine
whether these are important differences to be considered
in designing clinical trials. The male:female ratio of our
cohort was 0.84, but this did not significantly differ from
1.00, and there was no significant difference between
genders in the rate of increase of the SARA Total Score
from either retrospective estimate or prospective longi-
tudinal data in any SCA type. Longitudinal progression
studies in patients with SCAs have been conducted in
Taiwan [15] and Brazil [16], where progression charac-
teristics were similar to our series.
We defined the age at which an abnormality was noted
during usual walking as the age at onset. The age at on-
set could be even earlier if we defined it as the onset of
any ataxic symptom or sign. However, because of greater
inaccuracy of the recollection in those events compared
with that of gait disturbances, we decided to use the gait
as the mode of onset to judge the age at onset. Also we
could not be certain that some symptoms, such as blurred
vision, were not due to age-related non-ataxic ocular
problems. Furthermore, our data clearly showed that gait
abnormalities are the mode of onset in most patients.
The number of the CAGs in the expanded (mutant)
allele showed a significant inverse correlation with the
age at onset in SCA1, 2, 3 and SCA6. However, the
CAG expansion size showed no correlation with the rate
of increase of the SARA Total Score in patients with
SCA1, 2, 3 and 6 in our patients while other studies
showed mixed results [11,15-18]. The lack of correlation
between the CAG repeat expansion size and the disease
progression rate may suggest the presence of propor-
tionally greater confounding factors after the onset of
the disease.
Patients with SCA2 showed severe upper body ataxia,
such as speech, sitting stability and 9PHT. Patients with
SCA2 also showed frequent and prominent postural and
kinetic tremor enhanced by intention. Although the se-
verely impaired upper limb coordination in our SCA2
patients may at least be partly attributable to tremor,
tremor could not fully account for severe impairments
of speech and sitting balance. Thus, our data suggest
that SCA2 affects motor coordination in the upper body
more severely than that in the lower body. However, nei-
ther the observed rate of increase in the upper body
SARA score nor that in the lower body SARA score was
significantly different between SCA2 and other SCAs.
SCA2 may have disproportionally fast progression of
upper body ataxia in an early phase of the disease com-
pared with SCA1, 3 and 6.
As in the European study, the EQVAS score showed
no correlation to SARA scores in our patients. SCA-
specific measures of the quality of life are needed. However,
SF36 is widely used for various disorders, and non-pain
Table 3 Change in the SARA Total Score, functional stage, EQ-5D and SCAFI-AB from baseline to six-month visit
Global patient impression SARA Total Score Functional stage EQ-5D SCAFI-AB
N Mean STD N Mean STD N Mean STD N Mean STD
Stable 83 0.06 2.61 86 0.02 0.45 85 2.52 20.88 73 −0.02 0.39
Worse 132 0.95 2.64 132 0.21 0.51 129 −3.30 23.02 112 −0.09 0.34
Better 7 −0.86 2.06 7 −0.14 0.24 6 −3.50 18.43 6 0.18 0.48
All 222 0.56 2.65 225 0.13 0.49 220 −1.05 22.20 191 −0.06 0.36
Global physician impression SARA Total Score Functional stage EQ-5D SCAFI-AB
N Mean STD N Mean STD N Mean STD N Mean STD
Stable 103 0.18 2.33 108 0.04 0.46 105 −1.46 20.19 95 0.01 0.30
Worse 106 1.18 2.58 105 0.22 0.50 100 −2.13 23.68 88 −0.14 0.42
Better 14 −1.63 2.89 14 0.07 0.47 14 12.29 22.38 9 −0.06 0.33
All 223 0.54 2.58 227 0.13 0.49 219 −0.89 22.16 192 −0.06 0.37
Larger numbers reflect worse disease severity in the SARA Total Score and Functional Stage while the reverse applies to EQ-5D and SCAFI-AB.
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scores of SF36 may give a better correlation with SARA
scores.
None of the timed measures (T25FW, 9HPT and
SCAFI-AB) captured the faster progression of ataxia in
SCA1 than SCA2, 3 and 6. In T25FW, the devices used
to assist walking complicate the measurements. As in
the PATA test, results of these timed measures tend to
vary and this raises some doubt regarding the value of
composite measures, such as SCAFI and SCAFI-AB.
Conclusions
We conclude that disease progression rates in patients
with SCA1, 2, 3 and 6 are likely to be comparable be-
tween US and Europe. International collaborative clinical
studies, including therapeutic trials, may be feasible.
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